Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100

Differential Response of Breast Cancer Patients on E2100 Treated With Bevacizumab as a Function of Genetic Polymorphisms of VEGF and KDR

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00899418

Enrollment

500

Registered

2009-05-12

Start date

2006-05-31

Completion date

Unknown

Last updated

2013-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

recurrent breast cancer, stage IV breast cancer

Brief summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment. PURPOSE: This laboratory study is examining tumor tissue samples from patients with breast cancer treated with bevacizumab on clinical trial ECOG-2100 to learn more about DNA changes and response in these patients.

Detailed description

OBJECTIVES: Primary * Assess the effect of known variant polymorphisms (with functionally important associations) of the vascular endothelial growth factor (VEGF) gene on outcome (time to progression) in patients with breast cancer treated with bevacizumab on clinical trial ECOG-2100. Secondary * Assess the effect of known variant polymorphisms (with functionally important associations) of the VEGF receptor-2 (KDR) gene on outcome (time to progression) in these patients. * Assess the effect of known variant polymorphisms of these genes on efficacy (objective response rate and survival) in these patients. * Assess the effect of known variant polymorphisms of these genes on toxicity outcome in these patients. * Assess the effect of VEGF polymorphisms on VEGF expression by immunohistochemical staining (a known prognostic marker). * Assess the effect of KDR polymorphisms on KDR expression by immunohistochemical staining. OUTLINE: This is a multicenter study. Tissue and genomic DNA samples from paraffin-embedded primary tumor are examined using standard polymerase chain reaction (PCR) restriction fragment-length polymorphisms, immunohistochemistry, allele-specific PCR, and/or Taqman-based assays. Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (KDR) expression and polymorphisms are assessed. PROJECTED ACCRUAL: A total of 500 specimens will be accrued for this study.

Interventions

GENETICgene expression analysis

GENETICpolymerase chain reaction

GENETICpolymorphism analysis

OTHERimmunohistochemistry staining method

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed adenocarcinoma of the breast * Enrolled on clinical trial ECOG-2100 and received treatment with bevacizumab * Paraffin-embedded tumor samples available * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Female * Menopausal status not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Time to progression in patients with a known polymorphism vs those with wild-type vascular endothelial growth factor (VEGF) gene	—

Secondary

Measure	Time frame
Time to progression in patients with a known polymorphism vs those with wild-type VEGF receptor-2 (KDR) gene	—
Difference in response rate, survival, and toxicity in patients with a known polymorphism vs wild-type VEGF and KDR	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026